Sphingosine 1-phosphate and its regulatory role in vascular endothelial cells

• Yan Qiu ^[1] ; Junyi Shen ^[1] ; Wenli Jiang ^[1] ; Yi Yang ^[2] ; Xiaoheng Liu ^[1] ; Ye Zeng ^[1]
  1. [1] Sichuan University

     Sichuan University

     China

     
  2. [2] First Affiliated Hospital of Xinjiang Medical University

     First Affiliated Hospital of Xinjiang Medical University

     China

     
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 37, Nº. 3, 2022, págs. 213-226
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Sphingosine 1-phosphate (S1P) is a bioactive metabolite of sphingomyelin. S1P activates a series of signaling cascades by acting on its receptors S1PR1-3 on endothelial cells (ECs), which plays an important role in endothelial barrier maintenance, anti-inflammation, antioxidant and angiogenesis, and thus is considered as a potential therapeutic biomarker for ischemic stroke, sepsis, idiopathic pulmonary fibrosis, cancers, type 2 diabetes and cardiovascular diseases. We presently review the levels of S1P in those vascular and vascularrelated diseases. Plasma S1P levels were reduced in various inflammation-related diseases such as atherosclerosis and sepsis, but were increased in other diseases including type 2 diabetes, neurodegeneration, cerebrovascular damages such as acute ischemic stroke, Alzheimer's disease, vascular dementia, angina, heart failure, idiopathic pulmonary fibrosis, communityacquired pneumonia, and hepatocellular carcinoma.

    Then, we highlighted the molecular mechanism by which S1P regulated EC biology including vascular development and angiogenesis, inflammation, permeability, and production of reactive oxygen species (ROS), nitric oxide (NO) and hydrogen sulfide (H2S), which might provide new ways for exploring the pathogenesis and implementing individualized therapy strategies for those diseases.